Assets and liabilities of drug repositioning

Authors

  • RUPAM GILL Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka – 576104, India.
  • AMBERKAR MOHAN BABU V. Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka – 576104, India.
  • MEENA KUMARI K. Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka – 576104, India.

Keywords:

Chemical databases, Drug repurposing, Intellectual property rights, Off-target drug repositioning, Out-licensing

Abstract

Drug discovery is an awfully tenacious job that takes an enormous amount of time, resources, and money, yet yields unsubstantial results. Drug repositioning is a method for "discovering new uses for old drugs." The main objective to repurpose a drug is to extend the application line of an existing drug, thereby narrowing the productivity gap and at the same time allows a swift reach to the market with high chances of revenues. This approach aims at new formulations, dosage, drug combination, delivery system, alternative pathways and targets, orphan diseases. Likewise the de novo drug development, drug repositioning also shares many pros and cons. At one hand, drug repositioning offers relatively less risk-versus-reward ratio; on the other hand, the regulatory authority approval process, intellectual property rights and out-licensing are issues of concern. This review article will particularly focus on the various pros and cons associated with drug repositioning.

Published

31.12.2016

How to Cite

RUPAM GILL, AMBERKAR MOHAN BABU V., & MEENA KUMARI K. (2016). Assets and liabilities of drug repositioning. International Journal of Pharma and Bio Sciences, 7(4), 47–53. Retrieved from https://ijpbs.net/index.php/journal/article/view/5388

Issue

Section

Review Articles

Categories